fMRI and Opioid Abstinence
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorYale University
About this trial
This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.
Eligibility criteria
Qualifiers
recent initiation of methadone or buprenorphine at a clinic or program within the past year (i.e., period of time during which treatment drop-out and risk for relapse is highest);
eligibility for MRI scanning;
ability to commit to study visits.
Disqualifiers
current acute psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5;
current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment;
severe cognitive impairment as determined via trained clinical research staff through consent process and during consent quiz or as indicated by a PROMIS Cognitive Function tscore <30 (i.e., severe impairment)
past or present history of intellectual disability, developmental disorder, or neurological disease;
Trial design
Treatments tested in this trial
- fMRI
Treatment groups
240 Participants
are divided into 2 treatment groupsLocations
1The APT Foundation06520, New HavenConnecticut, United States
Sponsors and collaborators
Yale University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov